Rationale and Design of the Statins Evaluation in Coronary procedUres and REvascularization: The SECURE-PCI Trial

Publication date: Available online 8 January 2018 Source:American Heart Journal Author(s): Otavio Berwanger, Pedro G.M. de Barros e Silva, Frederico Toledo Campo Dall Orto, Pedro Beraldo de Andrade, Igor Ribeiro de Castro Bienert, Carlos Eduardo Bosso, José Mangione, Carisi Anne Polanczyk, Amanda Sousa, Renato Kalil, Luciano de Moura Santos, Andrei C. Sposito, Rafael L. Rech, Antonio Carlos Sobral Sousa, Felipe Baldissera, Bruno Ramos Nascimento, Isabella de Andrade Jesuíno, Eliana Vieira Santucci, Lucas Petri Daminani, Ligia N Laranjeira, Juliana A Borges de Oliveira, Roberto R Giraldez, Alexandre Biasi Cavalcanti, Sabrina Bernardez Pereira, Luiz Alberto Mattos, Luciana Vidal Armaganijan, Hélio Penna Guimarães, José Eduardo Sousa, John H. Alexander, Christopher B. Granger, Renato D. Lopes Background Previous evidence suggest that acute treatment with statins reduce atherosclerotic complications, including periprocedural MI, but, currently, there are no large, adequately-powered studies to define the effects of early, high-dose statins in patients with acute coronary syndrome (ACS) and planned invasive management. Objectives The main goal of Statins Evaluation in Coronary procedUres and REvascularization (SECURE-PCI) Trial is to determine whether the early use of a loading dose of 80mg of atorvastatin before an intended percutaneous coronary intervention (PCI), followed by an additional dose of 80mg 24 hours after the procedure, will be ...
Source: American Heart Journal - Category: Cardiology Source Type: research